# Switching from IV to SC vedolizumab in IBD: real-world effectiveness and safety over 48 weeks

Source: [Medical research : nature.com subject feeds](https://www.nature.com/articles/s44483-026-00008-z) · 2026-11-17 · Medicine
Page: https://themorning.science/story/switching-from-iv-to-sc-vedolizumab-in-ibd-real-world-effectiveness-and-safety-o-efa4d84f41aa9131
Kind: research · Impact: medium

## In brief

- A real-world study reports effectiveness and safety over 48 weeks after patients with IBD switched from IV to subcutaneous vedolizumab.
- The article is titled "Switching from IV to SC vedolizumab in IBD: real-world effectiveness and safety over 48 weeks" and appeared in the Nature subject feed on 2026-11-17.
- The source provided contains no summary, so specific results are not available here.

## Why it matters

For clinicians and patients, the study addresses whether moving from intravenous to subcutaneous vedolizumab keeps treatment effective and safe in everyday practice, not only in trials.

## Coverage

- [Switching from IV to SC vedolizumab in IBD: real-world effectiveness and safety over 48 weeks](https://www.nature.com/articles/s44483-026-00008-z) — Medical research : nature.com subject feeds, 2026-11-17

Tags: vedolizumab, inflammatory bowel disease, subcutaneous drug delivery, real-world evidence, ibd treatment

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
